β-内酰胺酶抑制剂联合不同β-内酰胺类抗生素对耐多药结核分枝杆菌临床菌株体外活性研究
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R969.3

基金项目:

河南省自然科学基金项目(232300420290);河南省科技攻关项目(222102310726)


In vitro activity of β-lactamase inhibitors combined with different β-lactam antibiotics against multidrug-resistant Mycobacterium tuberculosis clinical strains
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 文章评论
    摘要:

    目的 体外评估5种β-内酰胺类抗生素和不同β-内酰胺酶抑制剂组合对耐多药结核分枝杆菌(MDR-TB)活性的影响,以期发现针对耐多药结核病最有效的β-内酰胺类抗生素和β-内酰胺酶抑制剂组合。方法 选取2021年河南省耐药监测项目收集的MDR-TB菌株,使用最小抑菌浓度(MIC)法测定5种β-内酰胺类抗生素或联合β-内酰胺酶抑制剂对临床MDR-TB的MIC值,并采用聚合酶链式反应(PCR)和DNA测序法分析菌株的blaC突变情况。结果 共纳入105株MDR-TB,MIC检测结果显示,多尼培南对MDR-TB抗菌活性最高,其MIC50值为16 μg/mL。与β-内酰胺酶抑制剂联合后,大部分β-内酰胺类抗生素的MIC值明显下降。共有13.33%(14株)的菌株存在blaC基因的突变,主要为3种核苷酸替代突变,分别为AGT333AGG、AAC638ACC、ATC786ATT。BlaC蛋白Ser111Arg和Asn213Thr与同义单核苷酸突变相比,增强了克拉维酸/舒巴坦与美罗培南对MDR-TB的协同作用。结论 多尼培南和舒巴坦组合对MDR-TB具有最强的抗菌活性。而BlaC蛋白Ser111Arg和Asn213Thr的替代突变使MDR-TB对美罗培南的敏感性在克拉维酸/舒巴坦协同时增强。

    Abstract:

    Objective To evaluate the in vitro effect of combinations of 5 β-lactam antibiotics with different β-lactamase inhibitors on the activity of multidrug-resistant Mycobacterium tuberculosis (MDR-TB), and identify the most effective combination of β-lactam antibiotics and β-lactamase inhibitors against MDR-TB. Methods MDR-TB strains collected in Henan Province Antimicrobial Resistance Surveillance Project in 2021 were selected. The minimum inhibitory concentrations (MIC) of 5 β-lactam antibiotics or combinations with different β-lactamase inhibitors on clinically isolated MDR-TB strains were measured by MIC detection method, and the blaC mutation of the strains was analyzed by polymerase chain reaction (PCR) and DNA sequencing. Results A total of 105 strains of MDR-TB were included in the analysis. MIC detection results showed that doripenem had the highest antibacterial activity against MDR-TB, with a MIC50 of 16 μg/mL. MIC values of most β-lactam antibiotics decreased significantly after combined with β-lactamase inhibitors. A total of 13.33% (n=14) strains had mutations in blaC gene, mainly 3 nucleotide substitution mutations, namely AGT333AGG, AAC638ACC and ATC786ATT. BlaC proteins Ser111Arg and Asn213Thr enhanced the synergistic effect of clavulanic acid/sulbactam and meropenem on MDR-TB compared with synonymous single-nucleotide mutation. Conclusion The combination of doripenem and sulbactam has the strongest antibacterial activity against MDR-TB. Substitution mutations of BlaC protein Ser111Arg and Asn213Thr enhances the sensitivity of MDR-TB to meropenem through the synergy with clavulanic acid/sulbactam.

    参考文献
    相似文献
引用本文

石洁,郑丹薇,徐吉英,等.β-内酰胺酶抑制剂联合不同β-内酰胺类抗生素对耐多药结核分枝杆菌临床菌株体外活性研究[J]. 中国感染控制杂志,2024,23(9):1091-1097. DOI:10.12138/j. issn.1671-9638.20245121.
SHI Jie, ZHENG Dan-wei, XU Ji-ying, et al.In vitro activity of β-lactamase inhibitors combined with different β-lactam antibiotics against multidrug-resistant Mycobacterium tuberculosis clinical strains[J]. Chin J Infect Control, 2024,23(9):1091-1097. DOI:10.12138/j. issn.1671-9638.20245121.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-12-06
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-09-30
  • 出版日期: 2024-09-28